Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07060807 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Phase 3 study of Breast Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT07060807: Recruiting Phase 3 study of Breast Neoplasms, sponsored by Merck Sharp & Dohme.
NCT07060807 is a Phase 3 study of Breast Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,000 participants, above the 559-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07060807, a Phase 3 study of Breast Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
Primary Outcome
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by blinded independent central review (BICR). Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new le
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- BIOLOGICAL Patritumab deruxtecan
- DRUG Liposomal doxorubicin
Study Locations (20)
New Mexico
- Presbyterian Kaseman Hospital ( Site 0072) - Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0047) - Albuquerque
- Presbyterian Rust Jorgensen Cancer ( Site 0073) - Rio Rancho
California
- Los Angeles Hematology Oncology Medical Group ( Site 0026) - Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0025) - Newport Beach
Kentucky
- Baptist Health Lexington ( Site 0050) - Lexington
- Baptist Health Hamburg ( Site 0071) - Lexington
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) - Hackensack
- Rutgers Cancer Institute of New Jersey ( Site 0033) - New Brunswick
North Carolina
- Novant Health Cancer Institute ( Site 0019) - Charlotte
- Novant Health Oncology Specialists ( Site 0074) - Winston-Salem
Texas
- Texas Oncology - DFW ( Site 8003) - Dallas
- JPS Health Network ( Site 0067) - Fort Worth
Alabama
- Southern Cancer Center (SCC) ( Site 8000) - Daphne
Colorado
- St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021) - Grand Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2033-07-14 |
| Phase | Phase 3 |
What NCT07060807 shows while recruiting
NCT07060807 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 559-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (79% higher).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT07060807 names 20 study sites across 13 states, led by New Mexico, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT07060807 about?
NCT07060807 is a clinical study titled "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)". Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr...
What is the current status of trial NCT07060807?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2025-07-21. Estimated completion is 2033-07-14.
What conditions does trial NCT07060807 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT07060807?
The interventions under investigation include: Capecitabine (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), Patritumab deruxtecan (BIOLOGICAL), Liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT07060807?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07060807 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07060807's enrollment target sits among peer trials
1,000 10th of 97 higher than 87 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
-
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI